<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03027557</url>
  </required_header>
  <id_info>
    <org_study_id>180987</org_study_id>
    <secondary_id>2016-001510-20</secondary_id>
    <nct_id>NCT03027557</nct_id>
  </id_info>
  <brief_title>Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.</brief_title>
  <acronym>DENOCINA</acronym>
  <official_title>Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Vestergaard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aalborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aalborg University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The only known cure for primary hyperparathyroidism is surgical removal of one or more&#xD;
      parathyroid glands. Some patients however, do not fulfill criteria for surgery or do not want&#xD;
      to undergo a procedure due to fear of the associated risks. Therefore a medical alternative&#xD;
      is warranted.&#xD;
&#xD;
      This study aims to evaluate the effects of Denosumab alone, and in combination with&#xD;
      Cinacalcet, as a medical treatment for patients suffering from primary hyperparathyroidism,&#xD;
      with mild osteoporosis. To the best of our knowledge no previously reported randomized&#xD;
      controlled trial has investigated the use of denosumab in primary hyperparathyroidism.&#xD;
&#xD;
      60 patients will be enrolled in three different treatment-groups: 20 receiving both Denosumab&#xD;
      and Cinacalcet, 20 Denosumab and placebo and 20 placebo and placebo. Patients included do not&#xD;
      meet the criteria for, or have no wish for a surgical procedure.&#xD;
&#xD;
      By combining the two drugs, this study could possibly contribute to the discovery of a&#xD;
      realistic medical alternative to surgery. It is expected that the therapy will be able to&#xD;
      both control s-calcium and s-intact parathyroid hormone (iPTH), and simultaneously enhance&#xD;
      bone-structure. The therapy thus has the potential of preventing fractures and possibly other&#xD;
      long-term effects of primary hyperparathyroidism such as formation of kidney stones, and&#xD;
      coronary calcification. Another objective of this project is to investigate whether the&#xD;
      combined therapy can facilitate an actual reset of the Calcium-sensing receptor, and thereby&#xD;
      de facto cure the disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background/Context:&#xD;
&#xD;
      This project deals with medical treatment of primary hyperparathyroidism. The only cure&#xD;
      currently available is surgical removal of one or more parathyroid glands, but this option is&#xD;
      neither feasible, nor desirable in all patients with the diagnosis.&#xD;
&#xD;
      Today a major group of patients are being diagnosed by coincidence with biochemical&#xD;
      blood-screening, and are therefore in an asymptomatic state of the disease at the time of&#xD;
      diagnosis. Long term studies show that these patients over time often have progression in&#xD;
      their disease, and develop complications such as osteoporosis. Thus a medical alternative is&#xD;
      warranted.&#xD;
&#xD;
      Previous studies have investigated the effects of well known antiresorptive drugs such as&#xD;
      bisphosphonates, as well as estrogen-related compounds. These drugs have had effects on&#xD;
      particularly bone mineral density (BMD) and biochemical bone-turnover markers, but have been&#xD;
      able only transiently to lower blood-calcium levels. Combined with too many unwanted&#xD;
      side-effects and a high prevalence of contraindications for a large proportion of the&#xD;
      patients needing treatment, these drugs have not provided a realistic alternative to surgery.&#xD;
&#xD;
      Treatment today generally follows the international consensus for treatment of asymptomatic&#xD;
      patients with primary hyperparathyroidism. Briefly this includes watchful waiting with&#xD;
      biannual control-sessions for indication of surgery, screening for kidney&#xD;
      stones/nephrolithiasis, osteoporosis and s-calcium - and s-iPTH levels.&#xD;
&#xD;
      This randomized controlled trial involves the drugs Cinacalcet og Denosumab. Denosumab has&#xD;
      previously been shown to greatly improve BMD, lower s-calcium, lower the rate of&#xD;
      bone-turnover and prevent osteoporotic fractures in several populations with different&#xD;
      diseases, but has never been tested in a published randomized controlled trial in patients&#xD;
      with primary hyperparathyroidism.&#xD;
&#xD;
      Cinacalcet has been proved able to lower s-iPTH, lower s-Calcium and thereby relieve symptoms&#xD;
      of hypercalcaemia caused by primary hyperparathyroidism. It does not however, lower the rate&#xD;
      of bone turnover, and it has not been show to improve BMD.&#xD;
&#xD;
      By combining the two drugs, this study could possibly contribute to the discovery of a&#xD;
      realistic medical alternative to surgery. It is expected that the therapy will be able to&#xD;
      both control s-calcium and s-iPTH, and simultaneously enhance bone-structure. The therapy&#xD;
      thus has the potential of preventing fractures and possibly other long-term effects of&#xD;
      primary hyperparathyroidism such as formation of kidney stones, and coronary calcification.&#xD;
      Another objective of this project is to investigate whether the combined therapy can&#xD;
      facilitate an actual reset of the Calcium-sensing receptor, and thereby de facto cure the&#xD;
      disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">September 12, 2019</completion_date>
  <primary_completion_date type="Actual">April 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Lumbar Spine Bone Mineral Density</measure>
    <time_frame>Baseline,one year</time_frame>
    <description>Change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Total Hip Bone Mineral Density</measure>
    <time_frame>Baseline,one year</time_frame>
    <description>Change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Femoral Neck Bone Mineral Density</measure>
    <time_frame>Baseline,one year</time_frame>
    <description>Change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 1/3 Forearm Bone Mineral Density</measure>
    <time_frame>Baseline,one year</time_frame>
    <description>Change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Change in Lumbar Spine Bone Mineral Density</measure>
    <time_frame>Baseline,one year</time_frame>
    <description>Percentage change of Bone Mineral Density after one year of treatment from baseline.&#xD;
Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Change in Total Hip Bone Mineral Density</measure>
    <time_frame>Baseline,one year</time_frame>
    <description>Percentage change of Bone Mineral Density after one year of treatment from baseline.&#xD;
Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Change in Femoral Neck Bone Mineral Density</measure>
    <time_frame>Baseline,one year</time_frame>
    <description>Percentage change of Bone Mineral Density after one year of treatment from baseline.&#xD;
Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Change in 1/3 Forearm Bone Mineral Density</measure>
    <time_frame>Baseline,one year</time_frame>
    <description>Percentage change of Bone Mineral Density after one year of treatment from baseline.&#xD;
Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Volumetric BMD for the Lumbar Spine.</measure>
    <time_frame>Baseline, one year</time_frame>
    <description>Measured at baseline and after one year by QCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean P-calcium During Treatment.</measure>
    <time_frame>Monthly up to one year.</time_frame>
    <description>Blood samples were acquired once every 4 weeks for safety-purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in P-carboxy-terminal Collagen Crosslinks (CTX)</measure>
    <time_frame>Change from baseline at 48 weeks reported.</time_frame>
    <description>p-CTX, change from baseline at 48 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Agatstons Score Final</measure>
    <time_frame>Baseline, one year</time_frame>
    <description>Simultaneously with QCT-measurements coronary calcification was be assessed. Agatston score is a score based on the extent of coronary artery calcification calculated on the amount of plaque observed in a CT scan. A score of zero indicates absence of coronary calcium, 1-10: minimal calcification, 11-100 mild calcification, 101-400 moderate calcification, &gt;400 severe calcification.&#xD;
Thus the score increases with increasing level of calcification in the coronary vessels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Nephrolithiasis Final Scan.</measure>
    <time_frame>Patients with nephrolithiasis at one year reported.</time_frame>
    <description>Number of subjects w. renal stones at final scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Pancreas-calcifications Final Scan.</measure>
    <time_frame>Patients with pancreas-calcifications at one year reported.</time_frame>
    <description>By QCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reset of the Calcium Sensing Receptor?</measure>
    <time_frame>2 weeks after termination of medication.</time_frame>
    <description>Measured from effect on s-calcium and PTH weeks after termination of IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vertebral Fracture Assessment - Final Scan</measure>
    <time_frame>Patients with vertebral fractures at one year reported.</time_frame>
    <description>Number of participants with vertebral fractures as assessed by VFA at final scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change MDI-score</measure>
    <time_frame>Baseline, 6 mths, one year.</time_frame>
    <description>Major Depression Inventory (MDI)-score, Baseline, 6 months, one year (week 52)., change between baseline and 1 year reported.&#xD;
The Major Depression Inventory (MDI) is a mood questionnaire developed by the World Health Organization. To calculate the total score, a sum of ten individual items (each with an individual score between 0-5, with 0 indicating absence of a symptom and 5 indicating constant presence of a given symptom) is used. A higher score signifies deeper depression with 50 being the maximum score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Reactions.</measure>
    <time_frame>Monthly up to one year.</time_frame>
    <description>All participants filled in questionnaires regarding symptoms related to the treatment.&#xD;
Results are reported in the Adverse Events section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Content</measure>
    <time_frame>Baseline, one year</time_frame>
    <description>Measured at baseline and after one year at the lumbar spine and distal 1/3 of the non-dominant antebrachii.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cortical Width.</measure>
    <time_frame>Baseline, one year.</time_frame>
    <description>Measured at baseline and after one year at the distal non-dominant antebrachii.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Volumetric BMD for the Distal Forearm.</measure>
    <time_frame>Baseline, one year</time_frame>
    <description>Measured at baseline and after one year by QCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Volumetric BMD for the Lumbar Spine.</measure>
    <time_frame>Baseline, one year</time_frame>
    <description>Measured at baseline and after one year by QCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Volumetric BMD for the Distal Forearm.</measure>
    <time_frame>Baseline, one year</time_frame>
    <description>Measured at baseline and after one year by QCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean p-PTH During Treatment.</measure>
    <time_frame>Monthly up to one year.</time_frame>
    <description>Blood samples were acquired once every 4 weeks for safety-purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean p-Phosphate During Treatment.</measure>
    <time_frame>Monthly up to one year.</time_frame>
    <description>Blood samples were acquired once every 4 weeks for safety-purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in p-N-terminal Propeptide of Type I Procollagen (p-P1NP).</measure>
    <time_frame>Change from baseline at 48 weeks reported.</time_frame>
    <description>p-P1NP, change from baseline at 48 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in P-osteocalcin.</measure>
    <time_frame>Change from baseline at 48 weeks reported.</time_frame>
    <description>p-osteocalcin, change from baseline at 48 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in S-bone-specific Alkaline Phosphatase (BAP).</measure>
    <time_frame>Change from baseline at 48 weeks reported.</time_frame>
    <description>S-Bone specific alkaline phosphatase, change from baseline at 48 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in p-Tartrate-resistant Acid Phosphatase 5b (Trap5b).</measure>
    <time_frame>Change from baseline at 48 weeks reported.</time_frame>
    <description>P-Trap5b, change from baseline at 48 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in p-Sclerostin.</measure>
    <time_frame>Change from baseline at 48 weeks reported.</time_frame>
    <description>P-Sclerostin, change from baseline at 48 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in P-fibroblast Growth Factor 23 (FGF23).</measure>
    <time_frame>Change from baseline at 48 weeks reported.</time_frame>
    <description>P-FGF23 , change from baseline at 48 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in p-25-vitamin D</measure>
    <time_frame>Change from baseline at 48 weeks reported.</time_frame>
    <description>P-25-vitD , change from baseline at 48 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in s-1,25-vitamin D</measure>
    <time_frame>Change from baseline at 48 weeks reported.</time_frame>
    <description>S-1,25-vitD, change from baseline at 48 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Nephrocalcinosis, Final Scan.</measure>
    <time_frame>Baseline, one year</time_frame>
    <description>Number of subjects w. renal calcifications at final scan.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety Measures</measure>
    <time_frame>Monthly up to one year.</time_frame>
    <description>Biochemical measures of changes in liver, infection, kidney and electrolyte-status and urinary excretion of calcium.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Primary Hyperparathyroidism</condition>
  <condition>Parathyroid Adenoma</condition>
  <condition>Parathyroid Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Combined treatment.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 subjects will be treated with combined 60mg denosumab bi-annually , 30 mg cinacalcet daily and 50 micrograms vitamin-D daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 subjects will receive 60mg denosumab bi-annually, placebo and 50 micrograms vitamin-D daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 subjects will receive a saline injection bi-annually (blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cinacalcet 30 mg Tablet</intervention_name>
    <description>Participants in one arm will receive 30 mg cinacalcet each day.</description>
    <arm_group_label>Combined treatment.</arm_group_label>
    <other_name>Mimpara</other_name>
    <other_name>Sensipar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab Inj 60 mg/ml</intervention_name>
    <description>Participants in two arms will receive 60 mg Denosumab biannually.</description>
    <arm_group_label>Combined treatment.</arm_group_label>
    <arm_group_label>Monotherapy</arm_group_label>
    <other_name>Prolia</other_name>
    <other_name>Xgeva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo tablets</intervention_name>
    <description>Participants in two arms will receive one placebo-tablet each day.</description>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline Injection (Placebo)</intervention_name>
    <description>Participants in one arm will receive saline injections as placebo for denosumab.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sodium Chloride (NaCl) Fresenius &quot;Kabi&quot;</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women of 18 years of age or older.&#xD;
&#xD;
          -  T-score by Dual X-ray Absorptiometry (DXA) between -1,0 og -3,5&#xD;
&#xD;
          -  Patients from The North Jutland Region diagnosed with primary hyperparathyroidism at&#xD;
             the Department of Endocrinology, Aalborg University Hospital. (Hypercalcaemia measured&#xD;
             at two different time-points and simultaneous elevated/inappropriately high PTH, and&#xD;
             exclusion of differential diagnosis.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical history of diseases leading to hypercalcaemia other than Primary&#xD;
             Hyperparathyroidism.&#xD;
&#xD;
          -  Patients being treated with Denosumab or Cinacalcet prior to inclusion or previously&#xD;
             treated with Denosumab or Cinacalcet.&#xD;
&#xD;
          -  Moderately - Severely decreased liver function (alanine aminotransferase &gt;250u/l,&#xD;
             gamma-glutamyl transferase&gt;150u/l, Bilirubin &gt;30)&#xD;
&#xD;
          -  Acute myocardial infarction or apoplexia in the 3 months before inclusion.&#xD;
&#xD;
          -  Medical record of heart failure&#xD;
&#xD;
          -  Risk factors of prolonged corrected QT interval (QTc).&#xD;
&#xD;
          -  Open lesions from oral surgery.&#xD;
&#xD;
          -  Primary diseases of the bone other than osteoporosis.&#xD;
&#xD;
          -  Patients suffering from kidney disease or renal failure.&#xD;
&#xD;
          -  Patients under treatment with thiazide or lithium.&#xD;
&#xD;
          -  Medical record of generalized seizures or epilepsy.&#xD;
&#xD;
          -  Active malignant disease.&#xD;
&#xD;
          -  Known allergies towards the specified medicinal products (IMPs).&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Fertile women who do not agree to the usage of effective contraception.&#xD;
&#xD;
          -  Other circumstances, evaluated by the responsible investigator, making the subject&#xD;
             unsuitable for participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julius Simoni Leere, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg University and Aalborg University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Vestergaard, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Aalborg University and Aalborg University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 16, 2017</study_first_submitted>
  <study_first_submitted_qc>January 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2017</study_first_posted>
  <results_first_submitted>July 24, 2020</results_first_submitted>
  <results_first_submitted_qc>May 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 25, 2021</results_first_posted>
  <last_update_submitted>May 1, 2021</last_update_submitted>
  <last_update_submitted_qc>May 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University Hospital</investigator_affiliation>
    <investigator_full_name>Peter Vestergaard</investigator_full_name>
    <investigator_title>Professor, DMSc, Consultant</investigator_title>
  </responsible_party>
  <keyword>Primary Hyperparathyroidism</keyword>
  <keyword>Parathyroid Adenoma</keyword>
  <keyword>Parathyroid Hyperplasia</keyword>
  <keyword>Cinacalcet</keyword>
  <keyword>Denosumab</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Bone Mineral Density</keyword>
  <keyword>Calcium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Parathyroid Neoplasms</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Cinacalcet</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT03027557/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Combined Treatment.</title>
          <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
        </group>
        <group group_id="P2">
          <title>Denosumab Monotherapy</title>
          <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combined Treatment.</title>
          <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
        </group>
        <group group_id="B2">
          <title>Denosumab Monotherapy</title>
          <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.1" spread="13.2"/>
                    <measurement group_id="B2" value="65.4" spread="8.8"/>
                    <measurement group_id="B3" value="68.0" spread="7.0"/>
                    <measurement group_id="B4" value="66.15" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Denmark</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>T-score Lumbar Spine (LS) by Dual X-ray Absorptiometry (DXA)</title>
          <description>Baseline Bone mineral density (BMD) at lumbar spine (L2-L4) T-score. The T-score is the number of units that the bone density is above or below the average. -1 and above-bone density is considered normal; Between -1 and -2.5-is a sign of osteopenia, a condition in which bone density is below normal and may lead to osteoporosis. -2.5 and below-indicates osteoporosis</description>
          <units>T-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-1.9" spread="0.93"/>
                    <measurement group_id="B2" value="-2.0" spread="0.68"/>
                    <measurement group_id="B3" value="-1.3" spread="0.85"/>
                    <measurement group_id="B4" value="-1.7" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>T-score TH (by DXA)</title>
          <description>Baseline Bone mineral density (BMD) at Total Hip (TH) T-score. The T-score is the number of units that the bone density is above or below the average. -1 and above-bone density is considered normal; Between -1 and -2.5-is a sign of osteopenia, a condition in which bone density is below normal and may lead to osteoporosis. -2.5 and below-indicates osteoporosis.</description>
          <units>T-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-1.4" spread="0.5"/>
                    <measurement group_id="B2" value="-1.4" spread="0.6"/>
                    <measurement group_id="B3" value="-1.1" spread="0.5"/>
                    <measurement group_id="B4" value="-1.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>T-score FN (by DXA)</title>
          <description>Baseline Bone mineral density (BMD) at Femoral Neck (FN) T-score. The T-score is the number of units that the bone density is above or below the average. -1 and above-bone density is considered normal; Between -1 and -2.5-is a sign of osteopenia, a condition in which bone density is below normal and may lead to osteoporosis. -2.5 and below-indicates osteoporosis.</description>
          <units>T-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-2.0" spread="0.7"/>
                    <measurement group_id="B2" value="-1.9" spread="0.7"/>
                    <measurement group_id="B3" value="-1.7" spread="0.6"/>
                    <measurement group_id="B4" value="-1.88" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>T-score 1/3 FA (by DXA)</title>
          <description>Baseline Bone mineral density (BMD) at 1/3 distal forearm (1/3 FA)T-score. The T-score is the number of units that the bone density is above or below the average. -1 and above-bone density is considered normal; Between -1 and -2.5-is a sign of osteopenia, a condition in which bone density is below normal and may lead to osteoporosis. -2.5 and below-indicates osteoporosis.</description>
          <units>T-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-2.4" spread="1.2"/>
                    <measurement group_id="B2" value="-2.4" spread="1.2"/>
                    <measurement group_id="B3" value="-2.8" spread="0.9"/>
                    <measurement group_id="B4" value="-2.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Volumetric Bone Mineral Density (vBMD) LS</title>
          <description>Baseline lumbar spine BMD by quantitative computed tomography (QCT)</description>
          <units>mg/cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96.4" spread="28.1"/>
                    <measurement group_id="B2" value="99.7" spread="24.0"/>
                    <measurement group_id="B3" value="94.2" spread="25.4"/>
                    <measurement group_id="B4" value="96.9" spread="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>vBMD distal forearm</title>
          <description>Bone Mineral Density at the distal forearm by QCT</description>
          <units>mg/cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183.5" spread="32.0"/>
                    <measurement group_id="B2" value="194.9" spread="37.6"/>
                    <measurement group_id="B3" value="181.4" spread="35.5"/>
                    <measurement group_id="B4" value="192.6" spread="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cortical width</title>
          <description>Baseline cortical Width of the distal forearm.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.23" spread="0.5"/>
                    <measurement group_id="B2" value="1.19" spread="0.5"/>
                    <measurement group_id="B3" value="1.14" spread="0.4"/>
                    <measurement group_id="B4" value="1.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nephrolithiasis</title>
          <description>Subjects with nephrolithiasis at baseline</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nephrocalcinosis</title>
          <description>Subjects with nephrocalcinosis at baseline</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pancreas calcifications</title>
          <description>Subjects with pancreatic calcifications at baseline</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fracture by Vertebral Fracture Assessment (VFA)</title>
          <description>Subjects with vertebral fractures by VFA at baseline</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <description>Body Mass Index at baseline</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.7" spread="3.5"/>
                    <measurement group_id="B2" value="27.4" spread="4.8"/>
                    <measurement group_id="B3" value="28.4" spread="3.9"/>
                    <measurement group_id="B4" value="27.8" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ionized Calcium</title>
          <description>Baseline ionized calcium levels.</description>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.39" spread="0.08"/>
                    <measurement group_id="B2" value="1.39" spread="0.078"/>
                    <measurement group_id="B3" value="1.39" spread="0.08"/>
                    <measurement group_id="B4" value="1.39" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>P-Parathyroid Hormone (PTH)</title>
          <description>Baseline Parathyroid Hormone level.</description>
          <units>pmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.1" spread="6.2"/>
                    <measurement group_id="B2" value="13.1" spread="6.4"/>
                    <measurement group_id="B3" value="11.2" spread="4.3"/>
                    <measurement group_id="B4" value="12.1" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Agatston Score</title>
          <description>Agatston score is a score based on the extent of coronary artery calcification calculated on the amount of plaque observed in a CT scan. A score of zero indicates absence of coronary calcium, 1-10: minimal calcification, 11-100 mild calcification, 101-400 moderate calcification, &gt;400 severe calcification.&#xD;
Thus the score increases with increasing level of calcification in the coronary vessels.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.9" lower_limit="0.7" upper_limit="25.9"/>
                    <measurement group_id="B2" value="10.1" lower_limit="0.3" upper_limit="470.3"/>
                    <measurement group_id="B3" value="55.7" lower_limit="6.8" upper_limit="144.6"/>
                    <measurement group_id="B4" value="15.5" lower_limit="0.65" upper_limit="129.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>U-Calcium</title>
          <description>Baseline urine calcium excretion per day.</description>
          <units>mg/d</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="338" lower_limit="159" upper_limit="419"/>
                    <measurement group_id="B2" value="276" lower_limit="218" upper_limit="555"/>
                    <measurement group_id="B3" value="314" lower_limit="222" upper_limit="373"/>
                    <measurement group_id="B4" value="284" lower_limit="218" upper_limit="393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>U-Phosphorous</title>
          <description>Baseline daily excretion of phosphorous in urine.</description>
          <units>mmol/d</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.5" lower_limit="25.7" upper_limit="33.6"/>
                    <measurement group_id="B2" value="32.2" lower_limit="26.5" upper_limit="37.0"/>
                    <measurement group_id="B3" value="35.2" lower_limit="23.6" upper_limit="39.5"/>
                    <measurement group_id="B4" value="32.0" lower_limit="25.6" upper_limit="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>P-Phosphorous</title>
          <description>Baseline p-phosphorous.</description>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.77" spread="0.15"/>
                    <measurement group_id="B2" value="0.77" spread="0.16"/>
                    <measurement group_id="B3" value="0.79" spread="0.12"/>
                    <measurement group_id="B4" value="0.78" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Major Depression Inventory score</title>
          <description>The Major Depression Inventory (MDI) is a mood questionnaire developed by the World Health Organization. To calculate the total score, a sum of ten individual items (each with an individual score between 0-5, with 0 indicating absence of a symptom and 5 indicating constant presence of a given symptom) is used. A higher score signifies deeper depression with 50 being the maximum score.</description>
          <units>MDI-points</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5" lower_limit="2" upper_limit="11"/>
                    <measurement group_id="B2" value="5" lower_limit="1.5" upper_limit="8.5"/>
                    <measurement group_id="B3" value="5" lower_limit="2" upper_limit="7"/>
                    <measurement group_id="B4" value="5" lower_limit="2" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Lumbar Spine Bone Mineral Density</title>
        <description>Change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
        <time_frame>Baseline,one year</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lumbar Spine Bone Mineral Density</title>
          <description>Change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan.</population>
          <units>g/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.030" spread="0.009"/>
                    <measurement group_id="O2" value="0.042" spread="0.009"/>
                    <measurement group_id="O3" value="-0.016" spread="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.00001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Total Hip Bone Mineral Density</title>
        <description>Change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
        <time_frame>Baseline,one year</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. One participant from the placebo group did not provide results for this analysis as he/she had had a hip-replacement performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Hip Bone Mineral Density</title>
          <description>Change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. One participant from the placebo group did not provide results for this analysis as he/she had had a hip-replacement performed.</population>
          <units>g/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.027" spread="0.006"/>
                    <measurement group_id="O2" value="0.021" spread="0.003"/>
                    <measurement group_id="O3" value="-0.013" spread="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.00001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Femoral Neck Bone Mineral Density</title>
        <description>Change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
        <time_frame>Baseline,one year</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. One participant from the placebo group did not provide results for this analysis as he/she had had a hip-replacement performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Femoral Neck Bone Mineral Density</title>
          <description>Change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. One participant from the placebo group did not provide results for this analysis as he/she had had a hip-replacement performed.</population>
          <units>g/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.023" spread="0.006"/>
                    <measurement group_id="O2" value="0.020" spread="0.005"/>
                    <measurement group_id="O3" value="-0.007" spread="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.0019</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in 1/3 Forearm Bone Mineral Density</title>
        <description>Change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
        <time_frame>Baseline,one year</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. One participant from the denosumab group did not provide results for this analysis as he/she experienced a wrist fracture prior to the final scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 1/3 Forearm Bone Mineral Density</title>
          <description>Change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. One participant from the denosumab group did not provide results for this analysis as he/she experienced a wrist fracture prior to the final scan.</population>
          <units>g/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005" spread="0.003"/>
                    <measurement group_id="O2" value="0.005" spread="0.003"/>
                    <measurement group_id="O3" value="-0.005" spread="0.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.096</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Lumbar Spine Bone Mineral Density</title>
        <description>Percentage change of Bone Mineral Density after one year of treatment from baseline.&#xD;
Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
        <time_frame>Baseline,one year</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Lumbar Spine Bone Mineral Density</title>
          <description>Percentage change of Bone Mineral Density after one year of treatment from baseline.&#xD;
Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan.</population>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.1"/>
                    <measurement group_id="O2" value="5.1" spread="1.1"/>
                    <measurement group_id="O3" value="-1.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Total Hip Bone Mineral Density</title>
        <description>Percentage change of Bone Mineral Density after one year of treatment from baseline.&#xD;
Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
        <time_frame>Baseline,one year</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. One participant from the placebo group did not provide results for this analysis as he/she had had a hip-replacement performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Total Hip Bone Mineral Density</title>
          <description>Percentage change of Bone Mineral Density after one year of treatment from baseline.&#xD;
Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. One participant from the placebo group did not provide results for this analysis as he/she had had a hip-replacement performed.</population>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45" spread="0.72"/>
                    <measurement group_id="O2" value="2.64" spread="0.41"/>
                    <measurement group_id="O3" value="-1.50" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.00001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Femoral Neck Bone Mineral Density</title>
        <description>Percentage change of Bone Mineral Density after one year of treatment from baseline.&#xD;
Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
        <time_frame>Baseline,one year</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. One participant from the placebo group did not provide results for this analysis as he/she had had a hip-replacement performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Femoral Neck Bone Mineral Density</title>
          <description>Percentage change of Bone Mineral Density after one year of treatment from baseline.&#xD;
Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. One participant from the placebo group did not provide results for this analysis as he/she had had a hip-replacement performed.</population>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.70" spread="0.98"/>
                    <measurement group_id="O2" value="3.03" spread="0.86"/>
                    <measurement group_id="O3" value="-0.78" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.0027</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in 1/3 Forearm Bone Mineral Density</title>
        <description>Percentage change of Bone Mineral Density after one year of treatment from baseline.&#xD;
Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
        <time_frame>Baseline,one year</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. One participant from the denosumab group did not provide results for this analysis as he/she experienced a wrist fracture prior to the final scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in 1/3 Forearm Bone Mineral Density</title>
          <description>Percentage change of Bone Mineral Density after one year of treatment from baseline.&#xD;
Measured with Dual-energy X-ray absorptiometry (DXA)-scan.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. One participant from the denosumab group did not provide results for this analysis as he/she experienced a wrist fracture prior to the final scan.</population>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="0.7"/>
                    <measurement group_id="O2" value="0.88" spread="0.5"/>
                    <measurement group_id="O3" value="-0.91" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.081</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Volumetric BMD for the Lumbar Spine.</title>
        <description>Measured at baseline and after one year by QCT.</description>
        <time_frame>Baseline, one year</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. Another scan could not be included due to a technical problems with the image analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Volumetric BMD for the Lumbar Spine.</title>
          <description>Measured at baseline and after one year by QCT.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. Another scan could not be included due to a technical problems with the image analysis.</population>
          <units>mg/cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.93" spread="2.15"/>
                    <measurement group_id="O2" value="5.35" spread="1.91"/>
                    <measurement group_id="O3" value="-2.56" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.0071</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean P-calcium During Treatment.</title>
        <description>Blood samples were acquired once every 4 weeks for safety-purposes.</description>
        <time_frame>Monthly up to one year.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean P-calcium During Treatment.</title>
          <description>Blood samples were acquired once every 4 weeks for safety-purposes.</description>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>p-calcium measurements</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>p-calcium measurements</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="240"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="0.007"/>
                    <measurement group_id="O2" value="1.38" spread="0.006"/>
                    <measurement group_id="O3" value="1.40" spread="0.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in P-carboxy-terminal Collagen Crosslinks (CTX)</title>
        <description>p-CTX, change from baseline at 48 weeks.</description>
        <time_frame>Change from baseline at 48 weeks reported.</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in P-carboxy-terminal Collagen Crosslinks (CTX)</title>
          <description>p-CTX, change from baseline at 48 weeks.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.</population>
          <units>% change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.7" lower_limit="-73.2" upper_limit="-15.8"/>
                    <measurement group_id="O2" value="-58.2" lower_limit="-76.7" upper_limit="-44.3"/>
                    <measurement group_id="O3" value="11.8" lower_limit="1.96" upper_limit="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.0001</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Agatstons Score Final</title>
        <description>Simultaneously with QCT-measurements coronary calcification was be assessed. Agatston score is a score based on the extent of coronary artery calcification calculated on the amount of plaque observed in a CT scan. A score of zero indicates absence of coronary calcium, 1-10: minimal calcification, 11-100 mild calcification, 101-400 moderate calcification, &gt;400 severe calcification.&#xD;
Thus the score increases with increasing level of calcification in the coronary vessels.</description>
        <time_frame>Baseline, one year</time_frame>
        <population>Some participant from the combined and placebo groups could not be included in the analysis because they had coronary stents.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Agatstons Score Final</title>
          <description>Simultaneously with QCT-measurements coronary calcification was be assessed. Agatston score is a score based on the extent of coronary artery calcification calculated on the amount of plaque observed in a CT scan. A score of zero indicates absence of coronary calcium, 1-10: minimal calcification, 11-100 mild calcification, 101-400 moderate calcification, &gt;400 severe calcification.&#xD;
Thus the score increases with increasing level of calcification in the coronary vessels.</description>
          <population>Some participant from the combined and placebo groups could not be included in the analysis because they had coronary stents.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="0.0" upper_limit="78.1"/>
                    <measurement group_id="O2" value="24.3" lower_limit="0.7" upper_limit="602.1"/>
                    <measurement group_id="O3" value="117.8" lower_limit="6.8" upper_limit="182.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.38</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Nephrolithiasis Final Scan.</title>
        <description>Number of subjects w. renal stones at final scan.</description>
        <time_frame>Patients with nephrolithiasis at one year reported.</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Nephrolithiasis Final Scan.</title>
          <description>Number of subjects w. renal stones at final scan.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Pancreas-calcifications Final Scan.</title>
        <description>By QCT.</description>
        <time_frame>Patients with pancreas-calcifications at one year reported.</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Pancreas-calcifications Final Scan.</title>
          <description>By QCT.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reset of the Calcium Sensing Receptor?</title>
        <description>Measured from effect on s-calcium and PTH weeks after termination of IMP</description>
        <time_frame>2 weeks after termination of medication.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vertebral Fracture Assessment - Final Scan</title>
        <description>Number of participants with vertebral fractures as assessed by VFA at final scan.</description>
        <time_frame>Patients with vertebral fractures at one year reported.</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Vertebral Fracture Assessment - Final Scan</title>
          <description>Number of participants with vertebral fractures as assessed by VFA at final scan.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change MDI-score</title>
        <description>Major Depression Inventory (MDI)-score, Baseline, 6 months, one year (week 52)., change between baseline and 1 year reported.&#xD;
The Major Depression Inventory (MDI) is a mood questionnaire developed by the World Health Organization. To calculate the total score, a sum of ten individual items (each with an individual score between 0-5, with 0 indicating absence of a symptom and 5 indicating constant presence of a given symptom) is used. A higher score signifies deeper depression with 50 being the maximum score.</description>
        <time_frame>Baseline, 6 mths, one year.</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final collection of MDI-questionnaires.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change MDI-score</title>
          <description>Major Depression Inventory (MDI)-score, Baseline, 6 months, one year (week 52)., change between baseline and 1 year reported.&#xD;
The Major Depression Inventory (MDI) is a mood questionnaire developed by the World Health Organization. To calculate the total score, a sum of ten individual items (each with an individual score between 0-5, with 0 indicating absence of a symptom and 5 indicating constant presence of a given symptom) is used. A higher score signifies deeper depression with 50 being the maximum score.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final collection of MDI-questionnaires.</population>
          <units>MDI-score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-4.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-4.5" upper_limit="1.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-3.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.83</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Reactions.</title>
        <description>All participants filled in questionnaires regarding symptoms related to the treatment.&#xD;
Results are reported in the Adverse Events section.</description>
        <time_frame>Monthly up to one year.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Mineral Content</title>
        <description>Measured at baseline and after one year at the lumbar spine and distal 1/3 of the non-dominant antebrachii.</description>
        <time_frame>Baseline, one year</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Content</title>
          <description>Measured at baseline and after one year at the lumbar spine and distal 1/3 of the non-dominant antebrachii.</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cortical Width.</title>
        <description>Measured at baseline and after one year at the distal non-dominant antebrachii.</description>
        <time_frame>Baseline, one year.</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. One participant from the denosumab group experienced a wrist fracture prior to the final scan and was excluded. 4 patients did not provide data for the analysis due to errors in the technique of the obtained images.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cortical Width.</title>
          <description>Measured at baseline and after one year at the distal non-dominant antebrachii.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. One participant from the denosumab group experienced a wrist fracture prior to the final scan and was excluded. 4 patients did not provide data for the analysis due to errors in the technique of the obtained images.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.1"/>
                    <measurement group_id="O2" value="0.02" spread="0.08"/>
                    <measurement group_id="O3" value="0.04" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Volumetric BMD for the Distal Forearm.</title>
        <description>Measured at baseline and after one year by QCT.</description>
        <time_frame>Baseline, one year</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. One participant from the denosumab group experienced a wrist fracture prior to the final scan and was excluded. 5 patients did not provide data for the analysis due to errors in the technique of the obtained images.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Volumetric BMD for the Distal Forearm.</title>
          <description>Measured at baseline and after one year by QCT.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. One participant from the denosumab group experienced a wrist fracture prior to the final scan and was excluded. 5 patients did not provide data for the analysis due to errors in the technique of the obtained images.</population>
          <units>mg/cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="2.1"/>
                    <measurement group_id="O2" value="9.6" spread="3.7"/>
                    <measurement group_id="O3" value="-1.1" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.0077</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Volumetric BMD for the Lumbar Spine.</title>
        <description>Measured at baseline and after one year by QCT.</description>
        <time_frame>Baseline, one year</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. Another scan could not be included due to a technical problems with the image analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Volumetric BMD for the Lumbar Spine.</title>
          <description>Measured at baseline and after one year by QCT.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. Another scan could not be included due to a technical problems with the image analysis.</population>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.18" spread="3.14"/>
                    <measurement group_id="O2" value="5.66" spread="1.85"/>
                    <measurement group_id="O3" value="-2.94" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.011</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Volumetric BMD for the Distal Forearm.</title>
        <description>Measured at baseline and after one year by QCT.</description>
        <time_frame>Baseline, one year</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. One participant from the denosumab group experienced a wrist fracture prior to the final scan and was excluded. 5 patients did not provide data for the analysis due to errors in the technique of the obtained images.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Volumetric BMD for the Distal Forearm.</title>
          <description>Measured at baseline and after one year by QCT.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. One participant from the denosumab group experienced a wrist fracture prior to the final scan and was excluded. 5 patients did not provide data for the analysis due to errors in the technique of the obtained images.</population>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="1.2"/>
                    <measurement group_id="O2" value="5.2" spread="1.0"/>
                    <measurement group_id="O3" value="-0.74" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.011</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean p-PTH During Treatment.</title>
        <description>Blood samples were acquired once every 4 weeks for safety-purposes.</description>
        <time_frame>Monthly up to one year.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean p-PTH During Treatment.</title>
          <description>Blood samples were acquired once every 4 weeks for safety-purposes.</description>
          <units>pmol/l</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>p-PTH measurements</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>p-PTH measurements</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="240"/>
                <count group_id="O3" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="11.1" upper_limit="12.9"/>
                    <measurement group_id="O2" value="13.4" lower_limit="12.7" upper_limit="14.2"/>
                    <measurement group_id="O3" value="9.9" lower_limit="9.5" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.0001</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean p-Phosphate During Treatment.</title>
        <description>Blood samples were acquired once every 4 weeks for safety-purposes.</description>
        <time_frame>Monthly up to one year.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean p-Phosphate During Treatment.</title>
          <description>Blood samples were acquired once every 4 weeks for safety-purposes.</description>
          <units>pmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>p-phosphate measurements</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>p-phosphate measurements</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="240"/>
                <count group_id="O3" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.013"/>
                    <measurement group_id="O2" value="0.76" spread="0.012"/>
                    <measurement group_id="O3" value="0.083" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.00001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in p-N-terminal Propeptide of Type I Procollagen (p-P1NP).</title>
        <description>p-P1NP, change from baseline at 48 weeks.</description>
        <time_frame>Change from baseline at 48 weeks reported.</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in p-N-terminal Propeptide of Type I Procollagen (p-P1NP).</title>
          <description>p-P1NP, change from baseline at 48 weeks.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.</population>
          <units>% change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-63.1" lower_limit="-66.9" upper_limit="-57.2"/>
                    <measurement group_id="O2" value="-66.1" lower_limit="-75.9" upper_limit="-55.4"/>
                    <measurement group_id="O3" value="17.8" lower_limit="-11.0" upper_limit="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.0001</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in P-osteocalcin.</title>
        <description>p-osteocalcin, change from baseline at 48 weeks.</description>
        <time_frame>Change from baseline at 48 weeks reported.</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in P-osteocalcin.</title>
          <description>p-osteocalcin, change from baseline at 48 weeks.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.</population>
          <units>% change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60.0" lower_limit="-69.8" upper_limit="-36.9"/>
                    <measurement group_id="O2" value="-58.9" lower_limit="-66.9" upper_limit="-49.0"/>
                    <measurement group_id="O3" value="7.0" lower_limit="-0.9" upper_limit="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in S-bone-specific Alkaline Phosphatase (BAP).</title>
        <description>S-Bone specific alkaline phosphatase, change from baseline at 48 weeks.</description>
        <time_frame>Change from baseline at 48 weeks reported.</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in S-bone-specific Alkaline Phosphatase (BAP).</title>
          <description>S-Bone specific alkaline phosphatase, change from baseline at 48 weeks.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.</population>
          <units>% change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.0" lower_limit="-46.3" upper_limit="-24.1"/>
                    <measurement group_id="O2" value="-46.3" lower_limit="-51.5" upper_limit="-38.4"/>
                    <measurement group_id="O3" value="9.7" lower_limit="-7.9" upper_limit="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.0001</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in p-Tartrate-resistant Acid Phosphatase 5b (Trap5b).</title>
        <description>P-Trap5b, change from baseline at 48 weeks.</description>
        <time_frame>Change from baseline at 48 weeks reported.</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in p-Tartrate-resistant Acid Phosphatase 5b (Trap5b).</title>
          <description>P-Trap5b, change from baseline at 48 weeks.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.</population>
          <units>% change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.8" lower_limit="-34.1" upper_limit="-2.3"/>
                    <measurement group_id="O2" value="-36.7" lower_limit="-51.8" upper_limit="-16.4"/>
                    <measurement group_id="O3" value="2.3" lower_limit="-4.9" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in p-Sclerostin.</title>
        <description>P-Sclerostin, change from baseline at 48 weeks.</description>
        <time_frame>Change from baseline at 48 weeks reported.</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in p-Sclerostin.</title>
          <description>P-Sclerostin, change from baseline at 48 weeks.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.</population>
          <units>% change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="3.1" upper_limit="21.1"/>
                    <measurement group_id="O2" value="6.5" lower_limit="0.9" upper_limit="15.9"/>
                    <measurement group_id="O3" value="4.8" lower_limit="-2.3" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.5</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in P-fibroblast Growth Factor 23 (FGF23).</title>
        <description>P-FGF23 , change from baseline at 48 weeks.</description>
        <time_frame>Change from baseline at 48 weeks reported.</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in P-fibroblast Growth Factor 23 (FGF23).</title>
          <description>P-FGF23 , change from baseline at 48 weeks.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.</population>
          <units>% change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8" lower_limit="0.0" upper_limit="52.9"/>
                    <measurement group_id="O2" value="20.4" lower_limit="-13.6" upper_limit="58.2"/>
                    <measurement group_id="O3" value="28.0" lower_limit="-25.9" upper_limit="64.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.85</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in p-25-vitamin D</title>
        <description>P-25-vitD , change from baseline at 48 weeks.</description>
        <time_frame>Change from baseline at 48 weeks reported.</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in p-25-vitamin D</title>
          <description>P-25-vitD , change from baseline at 48 weeks.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.</population>
          <units>nmol/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" lower_limit="13.3" upper_limit="32.6"/>
                    <measurement group_id="O2" value="16.0" lower_limit="4.1" upper_limit="22.0"/>
                    <measurement group_id="O3" value="21.2" lower_limit="8.2" upper_limit="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.22</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in s-1,25-vitamin D</title>
        <description>S-1,25-vitD, change from baseline at 48 weeks.</description>
        <time_frame>Change from baseline at 48 weeks reported.</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in s-1,25-vitamin D</title>
          <description>S-1,25-vitD, change from baseline at 48 weeks.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.</population>
          <units>pmol/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="-4.0" upper_limit="35.0"/>
                    <measurement group_id="O2" value="4.5" lower_limit="-15.0" upper_limit="25.5"/>
                    <measurement group_id="O3" value="26.0" lower_limit="14.0" upper_limit="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.18</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Nephrocalcinosis, Final Scan.</title>
        <description>Number of subjects w. renal calcifications at final scan.</description>
        <time_frame>Baseline, one year</time_frame>
        <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Treatment.</title>
            <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab Monotherapy</title>
            <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Nephrocalcinosis, Final Scan.</title>
          <description>Number of subjects w. renal calcifications at final scan.</description>
          <population>One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Safety Measures</title>
        <description>Biochemical measures of changes in liver, infection, kidney and electrolyte-status and urinary excretion of calcium.</description>
        <time_frame>Monthly up to one year.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for each participant from baseline until two weeks after treatment-cessation, up to 1 year.</time_frame>
      <desc>Adverse events were collected at each visit using a adverse event questionnaire as well as assessment by a study-physician.</desc>
      <group_list>
        <group group_id="E1">
          <title>Combined Treatment.</title>
          <description>15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.</description>
        </group>
        <group group_id="E2">
          <title>Denosumab Monotherapy</title>
          <description>16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Polycythaemia Vera</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina, Unstable</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inflammatory Bowel Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" events="17" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" events="21" subjects_affected="9" subjects_at_risk="16"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" events="20" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" events="17" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E3" events="20" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia, hands</sub_title>
                <counts group_id="E1" events="36" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" events="15" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" events="20" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Paraesthesia, feet</sub_title>
                <counts group_id="E1" events="17" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" events="27" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" events="23" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Coughing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="9" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Leg edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="7" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Important limitations are the relatively small number of study-participants, and the lack of a cinacalcet monotherapy-arm.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Professor Peter Vestergaard</name_or_title>
      <organization>Aalborg University Hospital</organization>
      <phone>+45 97 66 36 00</phone>
      <email>p.vestergaard@rn.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

